Which Dividend Payer Did Hedge Funds Flock To In The Second Quarter?

Microsoft emerged as a darling for hedge funds in the second quarter, with 10 out of the 20 hedge funds with shares in their top-5 holdings for the quarter.

Microsoft Corp (NASDAQ:MSFT) emerged as a darling for hedge funds in the second quarter, with 10 out of the 20 hedge funds Benzinga analyzed having MSFT in their top-5 holdings for the quarter.

Microsoft’s widespread adoption among major institutional players isn’t surprising, particularly when you consider the tech giant’s performance year-to-date.

Shares skyrocketed by more than nearly 60%, touching highs of $366.78 before paring some of its gains. The surge can be attributed to the company’s substantial investments in artificial intelligence (AI) and a significant stake in OpenAI.

Outside of the AI fervor, those 10 hedge funds that owned the stock over the quarter were collectively paid nearly $22 million by the company. But it wasn’t from share appreciation, it was from dividends.

Here’s how the top hedge funds stack up based on their MSFT shares and the dividends they earned:

Rank Hedge Fund Shares Owned Dividend Payout
1 Fundsmith 9,012,591 $6.12 million
2 Tiger Global 5,668,918 $3.8 million
3 Eagle Capital 5,504,265 $3.74 million
4 Coatue Management 5,291,784 $3.59 million
5 Lone Pine Capital 2,502,085 $1.7 million
6 Altimeter Capital 1,533,135 $1.042 million
7 Whale Rock Capital 1,287,489 $875,492
8 Appaloosa Management 1,240,000 $843,200
9 Night Owl Capital 118,261 $80,417
10 Center Lake 85,000 $57,800
Institutional investors control 72.46% of Microsoft’s outstanding shares — that control not only gives them a say in corporate decisions but also makes them primary beneficiaries of dividends.

Warren Buffett’s investment in Apple Inc (NASDAQ:AAPL) is a great example in this regard. In just this year, Apple poured $645,350,303.61 into Berkshire Hathaway’s coffers, solely in dividends.

Retail traders — notably the newer generation — seem caught up in the volatility of today’s markets, and that frenzied pace often overshadows a foundational investment strategy: buy and hold.

Read Next: EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don’t?

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.

PRFX